JP2020519298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519298A5 JP2020519298A5 JP2019563082A JP2019563082A JP2020519298A5 JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5 JP 2019563082 A JP2019563082 A JP 2019563082A JP 2019563082 A JP2019563082 A JP 2019563082A JP 2020519298 A5 JP2020519298 A5 JP 2020519298A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- construct
- domain
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 230000003834 intracellular Effects 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108090001126 FURIN Proteins 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
Claims (17)
- （ａ）切断可能なドメイン；
（ｂ）第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第一のＣＡＲ；並びに
（ｃ）第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第二のＣＡＲ；
を含む、キメラ抗原受容体（ＣＡＲ）アミノ酸コンストラクトであって、
第一及び第二のＣＡＲが、切断可能なドメインを介して連結され、
（ｉ）第一の抗原結合ドメインが、配列番号４、６、及び８の重鎖可変領域ＣＤＲ配列、並びに配列番号１２、１４、及び１６の軽鎖可変領域ＣＤＲ配列を含み、且つ
第一のＣＡＲがコンストラクトから切断される場合、第一の抗原結合ドメインはＣＤ２２に対する抗原特異性を有するか；または、
（ｉｉ）第一の抗原結合ドメインが、配列番号２４、２６、及び２８の軽鎖可変領域ＣＤＲ配列、並びに配列番号３２、３４、及び３６の重鎖可変領域ＣＤＲ配列を含み、且つ
第一のＣＡＲがコンストラクトから切断される場合、第一の抗原結合ドメインはＣＤ１９に対する抗原特異性を有する、コンストラクト。 - 第一の抗原結合ドメインが、配列番号４、６、及び８の重鎖可変領域ＣＤＲ配列、並びに配列番号１２、１４、及び１６の軽鎖可変領域ＣＤＲ配列を含む、請求項１に記載のＣＡＲコンストラクト。
- 第一の抗原結合ドメインが、配列番号２４、２６、及び２８の軽鎖可変領域ＣＤＲ配列、並びに配列番号３２、３４、及び３６の重鎖可変領域ＣＤＲ配列のアミノ酸配列を含む、請求項１に記載のＣＡＲコンストラクト。
- 第二の抗原結合ドメインが、配列番号２４、２６、及び２８の軽鎖可変領域ＣＤＲ配列、並びに配列番号３２、３４、及び３６の重鎖可変領域ＣＤＲ配列を含む、請求項２に記載のＣＡＲコンストラクト。
- 切断可能なドメインが２Ａ又はフューリンである、請求項１〜４のいずれか１項に記載のＣＡＲコンストラクト。
- 切断可能なドメインが２Ａ及びフューリンである、請求項１〜４のいずれか１項に記載のＣＡＲコンストラクト。
- ＣＡＲコンストラクトが、それぞれ第一及び第二のＣＡＲである、ちょうど２つのＣＡＲを含む、請求項１〜６のいずれか１項に記載のＣＡＲコンストラクト。
- ＣＡＲが、配列番号４８、４９、５０、５１、若しくは５２のアミノ酸配列、又は配列番号６３〜７０のいずれか１と９０％以上の配列同一性を有するアミノ酸配列を含む、請求項１に記載のＣＡＲコンストラクト。
- ＣＡＲが、配列番号４９のアミノ酸配列を含む、請求項１に記載のＣＡＲ。
- （ａ）２以上の切断可能なドメイン；
（ｂ）第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第一のＣＡＲ；並びに
（ｃ）第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第二のＣＡＲ；
を含む、キメラ抗原受容体（ＣＡＲ）アミノ酸コンストラクトであって、
第一及び第二のＣＡＲが、２以上の切断可能なドメインを介して連結される、コンストラクト。 - ちょうど２つの切断可能なドメインが存在する、請求項１０のＣＡＲコンストラクト。
- 請求項１〜１１のいずれか１項のＣＡＲアミノ酸コンストラクトをコードするヌクレオチド配列を含む、核酸。
- 請求項１２の核酸を含む組換え発現ベクターを含む、単離された宿主細胞。
- 請求項１〜１１のいずれか１項のＣＡＲコンストラクト、請求項１２の核酸、請求項１３の宿主細胞又はその細胞集団と、医薬的に許容される担体とを含む、医薬組成物。
- 哺乳動物における、がんの治療のための医薬組成物であって、請求項１〜１１のいずれか１項のＣＡＲコンストラクト、請求項１２の核酸、請求項１３の宿主細胞若しくはその細胞集団、又は請求項１４の医薬組成物を有効成分として含む、医薬組成物。
- 前記がんが、血液悪性腫瘍である、請求項１５の医薬組成物。
- キメラ抗原受容体（ＣＡＲ）アミノ酸コンストラクトの作製方法であって、
（ａ）第一の抗原結合ドメイン、
第一の膜貫通ドメイン、及び
第一の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第一のＣＡＲ；並びに
（ｂ）第二の抗原結合ドメイン、
第二の膜貫通ドメイン、及び
第二の細胞内Ｔ細胞シグナル伝達ドメイン
を含む第二のＣＡＲ
の間に２以上の切断可能なドメインを設計し、第一及び第二のＣＡＲが該２以上の切断可能なドメインを介して連結されること；そして
第一のＣＡＲ、２以上の切断可能なドメイン、及び第二のＣＡＲを、Ｎ末端からＣ末端までに含む配列を、プラスミドにクローニングすること
を含む、方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506268P | 2017-05-15 | 2017-05-15 | |
| US62/506,268 | 2017-05-15 | ||
| PCT/US2018/032809 WO2018213337A1 (en) | 2017-05-15 | 2018-05-15 | Bicistronic chimeric antigen receptors and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519298A JP2020519298A (ja) | 2020-07-02 |
| JP2020519298A5 true JP2020519298A5 (ja) | 2021-07-26 |
Family
ID=62685125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563082A Pending JP2020519298A (ja) | 2017-05-15 | 2018-05-15 | バイシストロン性キメラ抗原受容体及びそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3625261A1 (ja) |
| JP (1) | JP2020519298A (ja) |
| KR (1) | KR20200005655A (ja) |
| CN (1) | CN110650975B (ja) |
| AU (1) | AU2018269194A1 (ja) |
| CA (1) | CA3062433A1 (ja) |
| WO (1) | WO2018213337A1 (ja) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738116B2 (en) | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| IT201800003464A1 (it) * | 2018-03-13 | 2019-09-13 | Ospedale Pediatrico Bambino Gesu | Cellule T CAR-CD30 per il trattamento di tumori CD30+ |
| WO2020123691A2 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc | Chimeric antigen and t cell receptors and methods of use |
| CA3125484A1 (en) | 2019-01-08 | 2020-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross-species single domain antibodies targeting mesothelin for treating solid tumors |
| EP3883971A1 (en) | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| KR20210129125A (ko) * | 2019-02-20 | 2021-10-27 | 시티 오브 호프 | Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도 |
| EP3952886A1 (en) * | 2019-04-10 | 2022-02-16 | Elevatebio Technologies, Inc | Flt3-specific chimeric antigen receptors and methods of using the same |
| GB201906283D0 (en) * | 2019-05-03 | 2019-06-19 | Moredun Res Institute | Vector |
| WO2020227446A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| WO2020243713A2 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| CN114729041A (zh) | 2019-10-22 | 2022-07-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体 |
| WO2021087245A1 (en) * | 2019-10-30 | 2021-05-06 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
| US11975026B2 (en) * | 2019-11-26 | 2024-05-07 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
| WO2021168000A1 (en) * | 2020-02-17 | 2021-08-26 | University Of Virginia Patent Foundation | CAR T CELLS TARGETING THE INTEGRIN ALPHAv BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES |
| CN113493516A (zh) * | 2020-04-02 | 2021-10-12 | 重庆精准生物技术有限公司 | 靶向双特异性位点的嵌合抗原受体及其应用 |
| CN113493517B (zh) * | 2020-04-02 | 2023-05-02 | 重庆精准生物技术有限公司 | 双特异性单链抗体及其构建的嵌合抗原受体和应用 |
| CN111632135A (zh) * | 2020-05-09 | 2020-09-08 | 深圳宾德生物技术有限公司 | 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物 |
| WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| CA3200509A1 (en) | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methods and compositions for modulating car-t activity |
| AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| CN112961245B (zh) * | 2021-02-24 | 2023-07-25 | 重庆精准生物技术有限公司 | 一种靶向cd96的双特异性抗体及其制备方法和用途 |
| WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| CA3219352A1 (en) | 2021-05-19 | 2022-11-24 | Sonja SCHREPFER | Hypoimmunogenic rhd negative primary t cells |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| WO2022261017A1 (en) | 2021-06-09 | 2022-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
| WO2023287827A2 (en) | 2021-07-14 | 2023-01-19 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| WO2023019229A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| CA3227613A1 (en) | 2021-08-11 | 2023-02-16 | William Dowdle | Inducible systems for altering gene expression in hypoimmunogenic cells |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
| WO2023086829A1 (en) | 2021-11-09 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
| WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN114478803B (zh) * | 2022-02-11 | 2023-09-26 | 北京大学深圳研究生院 | 一种新型双特异性嵌合抗原受体的构建及其应用 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023158986A1 (en) | 2022-02-15 | 2023-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889055C (en) * | 2012-10-24 | 2024-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
| WO2015090230A1 (en) * | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| DK3149031T3 (da) * | 2014-05-29 | 2020-03-16 | Us Health | Anti-human papillomavirus 16 e7 t-cellereceptorer |
| CA3224507A1 (en) * | 2014-12-24 | 2016-06-30 | Autolus Limited | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| US10738116B2 (en) * | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| RU2021121771A (ru) * | 2015-04-08 | 2022-01-12 | Новартис Аг | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 |
| CN115058395A (zh) * | 2015-06-25 | 2022-09-16 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| CN105647873A (zh) * | 2016-03-14 | 2016-06-08 | 紫程瑞生会(北京)生物技术发展有限公司 | 一种双特异性嵌合抗原受体基因修饰的自然杀伤细胞的制备方法及其试剂盒 |
-
2018
- 2018-05-15 AU AU2018269194A patent/AU2018269194A1/en active Pending
- 2018-05-15 CN CN201880032676.5A patent/CN110650975B/zh active Active
- 2018-05-15 CA CA3062433A patent/CA3062433A1/en active Pending
- 2018-05-15 KR KR1020197036903A patent/KR20200005655A/ko not_active Application Discontinuation
- 2018-05-15 EP EP18733012.1A patent/EP3625261A1/en active Pending
- 2018-05-15 WO PCT/US2018/032809 patent/WO2018213337A1/en unknown
- 2018-05-15 JP JP2019563082A patent/JP2020519298A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519298A5 (ja) | ||
| JP2019514361A5 (ja) | ||
| ES2773527T3 (es) | Receptor quimérico para antígeno | |
| JP2023139070A5 (ja) | ||
| JP2023071729A5 (ja) | ||
| JP2013509879A5 (ja) | ||
| JP2016502512A5 (ja) | ||
| JP2018531014A5 (ja) | ||
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| JP2019521643A5 (ja) | ||
| ES2356896T3 (es) | Anticuerpos humanizados contra icam-1, su producción y usos. | |
| JP2018529380A5 (ja) | ||
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| JP2018537087A5 (ja) | ||
| JP2017537627A5 (ja) | ||
| JP2020500015A5 (ja) | ||
| JP2018523484A (ja) | 細胞 | |
| JP2018536431A5 (ja) | ||
| CA2561826A1 (en) | Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody | |
| JP2018510639A5 (ja) | ||
| JP2008525033A5 (ja) | ||
| JP2018501794A5 (ja) | ||
| RU2017121892A (ru) | Клетка | |
| JP2013502226A5 (ja) | ||
| JP2010273685A5 (ja) |